 STONY BROOK, N.Y.--BUSINESS WIRE--- APDN LinearDNA--Applied DNA Sciences, Inc. NASDAQ: APDN the Company, a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied DNA and its majority-owned biotherapeutics subsidiary, LineaRx Inc., will present data highlighting the advantages of its enzymatically produced linearDNA linDNA as an IVT template for mRNA production at the 2nd Annual mRNA-Based Therapeutics Summit on July 26-28, 2022, in Boston, Massachusett 